Treatment for inflammatory and allergic disorders (IPP-201007)
Background
Phospholipases A2 (PLA2s) are enzymes that catalyze the hydrolysis of phospholipids. This catalytic reaction is essential in the production of lipids during various processes in the body, involving prostaglandins, leukotrienes, thromboxanes, platelet activation factor and others. In certain cases, such lipids mediators cause allergic reactions and a number of inflammatory conditions such as asthma and other respiratory disorders, rheumatoid arthritis, septic shock and acute pancreatitis are characterized by a significant increase in PLA2 activity.
ImmuPharma's compound
Selective inhibition of PLA2 subtypes can reduce some of these allergic reactions and inhibitors of PLA2 have already been shown to have positive effect in inflammatory conditions. ImmuPharma believes this new molecule has potential in becoming a drug for certain inflammatory conditions and intends to progress its development.
